Titlebook: Contemporary Pharmacotherapy of Overactive Bladder; Lindsey Cox,Eric S. Rovner Book 2019 Springer Nature Switzerland AG 2019 voiding dysfu

我不死扛

Esophagitis

Outcome Measures and Patient Expectations for Overactive Bladder, that is expeditious, easy to understand, complete, and provides a thorough assessment of the patient satisfaction or outcome. Providers may consider utilizing shared decision-making to set realistic expectations and choose a practical outcome measure specific to one’s clinical practice to optimize patient care and satisfaction.

爵士樂

,β3-Agonists for Overactive Bladder,ticholinergics and placebo is also addressed in this review. A growing body of evidence suggests that mirabegron is a safe and efficacious drug with a limited side effect profile rendering it as a potential first-line pharmacological option for the management of OAB.

diathermy

表主動

Individualizing Drug Therapy,ological properties of drugs, it also requires physicians and patients to have a candid discussion about treatment expectations in addition to counseling on drug side effects. Furthermore, patient comorbidities and age should be taken into consideration, as treatment should not create a hazardous situation for patients.

Synovial-Fluid

phase-2-enzyme

Other Treatments for Overactive Bladder, Including Intravesical, intravesical therapies have been tested, many with positive results. In this chapter, we will present scientific trials of agents that have been tested in human subjects. Familiarity with these studies will expand the treatment armamentarium for practicing urologists, better enabling them to treat this challenging group of patients.

挫敗

Creditee

hemoglobin

Antimuscarinic Pharmacotherapy for Overactive Bladder,nts are in common use including darifenacin, fesoterodine, hyoscyamine, imidafenacin, propantheline bromide, scopolamine, solifenacin, tolterodine, trospium, flavoxate, and oxybutynin. Important clinical data on these drugs is summarized in this chapter.